BGXX vs. IRD, SNYR, RNXT, GRCE, IXHL, JATT, AKTX, INKT, LEXX, and CMMB
Should you be buying Bright Green stock or one of its competitors? The main competitors of Bright Green include Opus Genetics (IRD), Synergy CHC Corp. (Uplisting) (SNYR), RenovoRx (RNXT), Grace Therapeutics (GRCE), Incannex Healthcare (IXHL), JATT Acquisition (JATT), Akari Therapeutics (AKTX), MiNK Therapeutics (INKT), Lexaria Bioscience (LEXX), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry.
Bright Green vs.
Bright Green (NASDAQ:BGXX) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk, community ranking and dividends.
Opus Genetics has a consensus target price of $8.00, indicating a potential upside of 595.65%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts plainly believe Opus Genetics is more favorable than Bright Green.
Opus Genetics has higher revenue and earnings than Bright Green. Opus Genetics is trading at a lower price-to-earnings ratio than Bright Green, indicating that it is currently the more affordable of the two stocks.
7.8% of Bright Green shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 62.5% of Bright Green shares are owned by insiders. Comparatively, 6.6% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Bright Green has a net margin of 0.00% compared to Opus Genetics' net margin of -324.45%. Opus Genetics' return on equity of -63.65% beat Bright Green's return on equity.
Bright Green has a beta of -0.26, meaning that its stock price is 126% less volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500.
Opus Genetics received 2 more outperform votes than Bright Green when rated by MarketBeat users.
In the previous week, Opus Genetics had 2 more articles in the media than Bright Green. MarketBeat recorded 2 mentions for Opus Genetics and 0 mentions for Bright Green. Bright Green's average media sentiment score of 0.00 equaled Opus Genetics'average media sentiment score.
Summary
Opus Genetics beats Bright Green on 10 of the 15 factors compared between the two stocks.
Get Bright Green News Delivered to You Automatically
Sign up to receive the latest news and ratings for BGXX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Bright Green Competitors List
Related Companies and Tools
This page (NASDAQ:BGXX) was last updated on 2/14/2025 by MarketBeat.com Staff